GH RESEARCH PLC (GHRS) Stock Price, Quote, News and Overview
NASDAQ:GHRS - Nasdaq - IE000GID8VI0 - Common Stock - Currency: USD
GHRS Quote, Performance and Key Statistics
10.5
-0.05 (-0.47%)
The current stock price of GHRS is 10.5 USD. In the past month the price decreased by -22.28%. In the past year, price increased by 29.47%.
GHRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.89 | 824.51B | ||
| JNJ | JOHNSON & JOHNSON | 16.69 | 401.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.18 | 386.95B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.41 | 240.28B | ||
| MRK | MERCK & CO. INC. | 12.39 | 239.09B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.56 | 228.26B | ||
| PFE | PFIZER INC | 8.59 | 151.49B | ||
| SNY | SANOFI-ADR | 14.24 | 148.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 53.59 | 123.97B | ||
| GSK | GSK PLC-SPON ADR | 8.29 | 81.62B | ||
| ZTS | ZOETIS INC | 28.78 | 76.29B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.71 | 47.88B |
Related stock screener links
About GHRS
Company Profile
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 49 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Company Info
GH RESEARCH PLC
Joshua Dawson House, Dawson Street
DUBLIN LEINSTER IE
CEO: Theis Terwey
Employees: 49
Company Website: http://www.ghres.com
Investor Relations: https://investor.ghres.com/
Phone: 35314378334
GH RESEARCH PLC / GHRS FAQ
What is the stock price of GH RESEARCH PLC today?
The current stock price of GHRS is 10.5 USD. The price decreased by -0.47% in the last trading session.
What is the ticker symbol for GH RESEARCH PLC stock?
The exchange symbol of GH RESEARCH PLC is GHRS and it is listed on the Nasdaq exchange.
On which exchange is GHRS stock listed?
GHRS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GH RESEARCH PLC stock?
12 analysts have analysed GHRS and the average price target is 32.64 USD. This implies a price increase of 210.86% is expected in the next year compared to the current price of 10.5. Check the GH RESEARCH PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GH RESEARCH PLC worth?
GH RESEARCH PLC (GHRS) has a market capitalization of 651.32M USD. This makes GHRS a Small Cap stock.
How many employees does GH RESEARCH PLC have?
GH RESEARCH PLC (GHRS) currently has 49 employees.
What are the support and resistance levels for GH RESEARCH PLC (GHRS) stock?
GH RESEARCH PLC (GHRS) has a support level at 10.12 and a resistance level at 10.51. Check the full technical report for a detailed analysis of GHRS support and resistance levels.
Should I buy GH RESEARCH PLC (GHRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GHRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GHRS, evaluating the profitability, health, valuation and growth aspects
- GH RESEARCH PLC (GHRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GH RESEARCH PLC (GHRS) Sales and EPS estimates to see what analysts future expectations are.
- GH RESEARCH PLC (GHRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GH RESEARCH PLC (GHRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- GH RESEARCH PLC (GHRS) Stock Chart to make your own analysis
- GH RESEARCH PLC (GHRS) Latest news and press-releases to stay up to date.
Does GH RESEARCH PLC (GHRS) stock pay dividends?
GHRS does not pay a dividend.
What is the Price/Earnings (PE) ratio of GH RESEARCH PLC (GHRS)?
GH RESEARCH PLC (GHRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
What is the Short Interest ratio of GH RESEARCH PLC (GHRS) stock?
The outstanding short interest for GH RESEARCH PLC (GHRS) is 7.01% of its float. Check the ownership tab for more information on the GHRS short interest.
GHRS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GHRS. When comparing the yearly performance of all stocks, GHRS is one of the better performing stocks in the market, outperforming 93.29% of all stocks.
GHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GHRS. While GHRS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GHRS Financial Highlights
Over the last trailing twelve months GHRS reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS decreased by -10.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.83% | ||
| ROE | -18.79% | ||
| Debt/Equity | 0 |
GHRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GHRS. The Buy consensus is the average rating of analysts ratings from 12 analysts.